Bismuth Quadruple Therapy With Cefuroxime for Helicobacter Pylori Eradication Treatment

• Status: Not yet recruiting
• Trial end date: 2022-12-31
• Target enrollment: 0
• Participant gender: All

Summary

To observe the efficacy of cefuroxime-containing bismuth quadruple regimen in the eradication treatment of Helicobacter pylori, and to evaluate whether it can be used as a remedial treatment for Helicobacter pylori after initial or repeated treatment failure.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shanghai East Hospital
• Treatments: Bismuth; Cefuroxime; Cefuroxime axetil

Criteria

Inclusion Criteria:

• Employees, family members, and patients with positive C13 breath test in our hospital;

• Has received one or more previous Helicobacter pylori eradication therapy (no use of cefuroxime or tetracycline), and the result is still positive by C13 breath test;

• Willing to undergo gastroscopy and HP cultivation and identification;

• Age 18-70, gender unlimited;

• Willing to participate in and cooperate with the study, and willing to sign the informed consent.

Exclusion Criteria:

• Drugs that may affect the study results, such as PPI, H2 blockers, bismuth agents, antibiotics, etc. were taken in the 4 weeks before enrollment;

• Patients with gastrointestinal malignancy tumor;

• Patients with gastrinoma;

• After gastric or esophageal surgery;

• Suffers from serious diseases of the heart, lung, kidney, liver, blood, nervous system, endocrine system or mental system;

• Patients with contraindications or previous allergic reactions to the drugs used in this study;

• Pregnant or breastfeeding women;

• Patients with other medical conditions that may increase the treatment side effects;

• Those who cannot give informed consent;

• Has participated in other drug trials within 3 months;

• Not considered suitable for participants by the investigator.